Encequidar, HCl - CAS 849675-88-3

Encequidar, also known as HM-30181, is an oral P-glycoprotein (P-gp) inhibitor developed to enhance the oral bioavailability of P-gp substrate drugs. Encequidar showed the highest potency (IC (50) =0.63nM) among several MDR1 inhibitors, including cycloporin A, XR9576, and GF120918, and effectively blocked transepithelial transport of paclitaxel in MDCK monolayers (IC (50) =35.4nM) . Encequidar is currently under clinical trials.

P-gp, Others

Neuroscience, Others, Membrane transporter/Ion channel

849584

C38H37ClN6O7

725.2

Cl.COc1cc2CCN(CCc3ccc(cc3)-n3nnc(n3)-c3cc(OC)c(OC)cc3NC(=O)c3cc(=O)c4ccccc4o3)Cc2cc1OC

-20°C

Ice Packs

Small Compound